Carbajal Hector, Soltero Liliana, Rodríguez-Montalvo Carlos, Valdés Alejandro
Escuela de Medicina, Ignacio A. Santos del Instituto Tecnologicóy de Estudios Superiores de Monterrey and the State of Nuevo León Organ and Tissue Transplant Registry, Monterrey, Mexico.
Transplantation. 2004 Apr 15;77(7):1038-40. doi: 10.1097/01.tp.0000122343.51904.c3.
The high cost of cyclosporine A (CsA) is an impediment for low-income patients. Previous studies have used ketoconazole at doses between 200 and 400 mg/day to lower CsA consumption.
Ketoconazole and CsA were administered prospectively to renal transplant patients. Patients treated historically with CsA were used as a reference group. At different intervals posttransplant, clinical and laboratory data were recorded.
The reference group (n=14) was treated with CsA from 1992 to 1997 and the CsA plus ketoconazole group (n=17) from 1998 to 2002. Follow-up was 76+/-22 and 29+/-14 months, respectively. CsA doses throughout the study were 4.0+/-1.3 and 1.6+/-0.6 mg/kg/day (a 60% reduction, P =0.00). Trough levels of CsA were 194+/-87 and 193+/-69 ng/mL, respectively. The ketoconazole dose was 54+/-17 mg/day. The monthly cost of CsA was reduced by 60%, including the cost of ketoconazole.
CsA with ketoconazole resulted in a substantial dose and cost reduction that proved safe and effective.
